MDK was highly expressed specifically in SLS cells, and MDK inhibitor treatment enhanced the therapeutic effect of rapamycin in patient-derived TSC2-deficient AML cells in vitro and in vivo. This evidence concerns the gene TSC2 and acute myeloid leukemia.